GSK says antibody drug ‘Sotrovimab’ works against Omicron, Health News, ET HealthWorld
GlaxoSmithKline on Thursday said that a pre-clinical analysis of the antibody-based COVID-19 has indicated that the drug also works against the new Omicron variant. Further tests will be carried out on the sotrovimab therapy to firm up the results, GSK said in a statement.
Xevudy (sotrovimab) was approved after it was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease. It was found to reduce the risk of hospitalisation and death by 79% in high-risk adults with symptomatic COVID-19 infection in clinical trials.
However, MHRA has said that it is too early to know whether the omicron variant has any impact on sotrovimab’s effectiveness. Like molnupiravir, it has been authorised for use in people who have mild to moderate COVID-19 infection and at least one risk factor for developing severe illness. Such risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease, the MHRA said. Sotrovimab is not intended to be used as a substitute for vaccination against COVID-19.